News
AQST
2.795
+4.68%
0.125
Weekly Report: what happened at AQST last week (0708-0712)?
Weekly Report · 8h ago
New Strong Sell Stocks for July 11th
NASDAQ · 4d ago
Weekly Report: what happened at AQST last week (0701-0705)?
Weekly Report · 07/08 11:17
Weekly Report: what happened at AQST last week (0624-0628)?
Weekly Report · 07/01 11:18
Optimistic Outlook for Aquestive Therapeutics’ Anaphylm with Positive PK Results and Strategic FDA Engagement
TipRanks · 06/28 07:56
Aquestive Therapeutics Price Target Maintained With a $9.00/Share by JMP Securities
Dow Jones · 06/26 16:13
JMP Securities Reiterates Market Outperform on Aquestive Therapeutics, Maintains $9 Price Target
Benzinga · 06/26 16:03
Buy Rating Affirmed for Aquestive Therapeutics as Anaphylm Shows Promising Stability and Progresses Towards FDA Submission
TipRanks · 06/25 20:15
ARS Pharmaceuticals On Track With Neffy Despite Regulatory Hurdles
Seeking Alpha · 06/25 18:10
Oral Allergy Medication For Emergencies - Aquestive Therapeutics' Investigational Therapy Works Even With Exposure To Liquids Of Different Temperatures, Data Shows
Aquestive Therapeutics Inc (NASDAQ:AQST) released data from the temperature / pH study of its product candidate Anaphylm (epinephrine) Sublingual Film. The company is developing the product for severe life-threatening allergic reactions, including anaphylaxis. The study showed no statistically significant difference in the absorption levels of the drug.
Benzinga · 06/25 17:00
Aquestive gains after initial data for allergy candidate
Aquestive gains after initial data for allergy candidate Anaphylm. Aquestive Therapeutics announces topline trial results for its product candidate. The drug is targeted at various allergic reactions, including anaphylaxis, a fatal hypersensitivity reaction .
Seeking Alpha · 06/25 13:29
Aquestive Therapeutics (AQST) Gets a Buy from Lake Street
TipRanks · 06/25 12:55
Aquestive Therapeutics Reports Topline Data From Temperature / pH Study Of Anaphylm Sublingual Film
Anaphylm pharmacokinetic results unaffected by oral cavity exposure to liquids of different temperatures and pH Remains on track to complete Anaphyl m supportive clinical studies and expects to request pre-NDA meeting with FDA in the third quarter 2024. Aquestive Therapeutics anticipates filing a New Drug Application shortly after completion of its pediatric study of Anaphylem. Anaphlym is the Company's epinephrine product candidate.
Benzinga · 06/25 12:05
AQUESTIVE THERAPEUTICS: SEES FILING NDA SHORTLY AFTER COMPLETION OF PEDIATRIC STUDY OF ANAPHYLM
Reuters · 06/25 12:04
Weekly Report: what happened at AQST last week (0617-0621)?
Weekly Report · 06/24 11:26
Aquestive Therapeutics to join Russell 3000 and Russell 2000 indexes
Healthcare Aquestive Therapeutics to join Russell 3000 and Russell 2000 indexes Jun. 18, 2024. AQST +0.73% premarket to $2.75. The company is expected to be added to the broad-market Russell3000 andRussell 2000 Indexes.
Seeking Alpha · 06/18 12:43
Weekly Report: what happened at AQST last week (0610-0614)?
Weekly Report · 06/17 11:16
Weekly Report: what happened at AQST last week (0603-0607)?
Weekly Report · 06/10 11:19
Aquestive Therapeutics Shares Investor Presentation Update
TipRanks · 06/07 12:58
Aquestive Therapeutics Appoints Cassie Jung as COO
TipRanks · 06/06 21:13
More
Webull provides a variety of real-time AQST stock news. You can receive the latest news about Aquestive Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About AQST
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies. It is advancing a product pipeline for the treatment of severe allergic reactions, including anaphylaxis. It has also developed a product pipeline focused on treating diseases of the central nervous system (CNS). Its PharmFilm technology is comprised of proprietary polymer compositions that serve as film formers to hold active pharmaceutical ingredients (APIs), and excipients in place. Its product portfolio and pipeline include Anaphylm, AQST-108, and Adrenaverse. Its CNS product candidate include Libervant. The Company’s Licensed commercial products and product candidates and other product includes Suboxone, Exservan, KYNMOBI, Zuplenz, Azstarys, Libervant, and Sympazan. Anaphylm is a non-device based, orally delivered epinephrine product candidate.